Interim 2017/18 influenza seasonal vaccine effectiveness. Combined results from five European studies

01 Pubblicazione su rivista
Rondy M, Kissling E, Emborg Hd, Gherasim A, Pebody R, Trebbien R, Pozo F, Larrauri A, Mcmenamin J, Valenciano M, Kaic B, Kurecic Filipovic S, Visekruna-Vucina V, Pem Novosel I, Lovric Z, Petrovi? G, Krause Tg, Fischer Tk, Lina B, Falchi Antonella, Vilcu Am, Souty C, Blanchon T, van der Werf S, Enouf V, Behillil S, Valette M, Bernard-Stoecklin S, Lévy-Bruhl D, Launay O, Loulergue P, Lenzi N, Lesieur Z, L'Honneur As, Galtier F, Agostini C, Serrand C, Merle C, Foulongne V, Vanhems P, Lainé F, Lagathu G, Carrat F, Buda S, Preuss U, Prahm K, Schweiger B, Wedde M, Heider A, Martin M, Biere B, Duerrwald R, Domegan L, Coughlan L, O’Donnell J, Joyce M, Collins C, Dunford L, Moran J, Tuite G, Duffy M, Connell J, de Gascun C, Rizzo C, Bella A, Alfonsi V, Castrucci Mr, Puzelli S, Pagani E, Ghisetti V, Pariani E, Baldanti F, Palù G, D'Agaro P, Ansaldi F, Affanni P, Rossolini Gm, Camilloni B, Bagnarelli P, Sanguinetti M, Atripaldi L, Chironna M, Serra C, Vitale F, Chironna M, Germinario C, Orsi A, Ansaldi F, Manini I, Montomoli E, Napoli C, Orsi Gb, Casado I, Castilla J, Fernandino L, Martínez-Baz I, Ezpeleta G, Navascués A, Pérez-García A, Aguinaga A, Ezpeleta C, Meijer A, van den Brink S, van der Hoek W, Goderski G, Wijsman L, Bagheri M, Dijkstra F, de Lange M, Marzec T, Overduin P, Teirlinck A, Wentink E, Donker G, Marbus S, van Gageldonk- Lafeber R, Schneeberger P, van Oosterheert Jj, Schweitzer V, Groeneveld G, Nunes B, Machado A, Rodrigues Ap, Gomez V, Kislaya I, Guiomar R, Pechirra P, Cristóvão P, Costa I, Panarra A, Côrte-Real R, Poças J, João Peres M, Larrauri A, Gherasim A, Pozo F, García Comas L, Marisquerena Mei, Galán Jc, Folgueira D, Gonzalez Carril F, Sancho Martínez R, Cilla G, Castilla J, García Cenoz M, Navascués A, Quiñones Rubio C, Martinez Ochoa E, Blasco M, Gimenez Duran J, Vanrell Jm, Reina J, Castrillejo D, Larrauri A, Gherasim Am, Delgado C, Oliva J, Casas I, Larrauri A, Gherasim Am, Pozo F, Casas I, García M, Latorre M, Milagro Beamonte Am, Martinez Sapiñ A, Oribe Amores M, Aizpurúa A, Cilla G, Montes M, Zakikhany K, Brytting M, Wiman Å, Carnahan A, Pebody R, Warburton F, Djennad A, Ellis J, Andrews N, Marques D, Cottrell S, Reynolds A, Gunson R, Galiano M, Lackenby A, Robertson C, O’Doherty M, Sinnathamby M, Yonova I, Moore C, Sartaj M, de Lusignan S, Mcmenamin J, Zambon M, Valenciano M, Moren A, Kissling E, Rondy M, Penttinen P.
ISSN: 1560-7917

Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma